Main Line Health’s Community Clinical Oncology Program One of Only 34 U.S. Sites Designated by the National Cancer Institute as a Community Oncology Research Program

Wednesday, August 13, 2014

Lankenau Institute for Medical Research, the biomedical research center for Main Line Health, received a $3.1 million, five-year grant award from the National Cancer Institute (NCI) to conduct clinical trials of new oncology drugs and perform additional research to improve patient care.

This award for an NCI Community Oncology Research Program (NCORP) supports all NCI-sponsored clinical trials, which is conducted by Main Line Health oncologists, relates to cancer prevention, screening, treatment and post-treatment management. NCORP also supports research into cancer care delivery, which focuses on improving health and quality of life outcomes, identifying and addressing any disparities of care among individual patients, and gaining a more integrated understanding of all the costs involved in effective health management.

Main Line Health is one of only 34 health care organizations in the U.S. to receive an NCORP award from NCI, testifying to the national strengths of the Main Line Health hospitals in delivering and continuously improving cancer care. NCORP supports oncology research at all Main Line Health hospitals, including Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital.

The Principal Investigator for the Main Line Health NCORP award is Albert DeNittis, MD, Chief of Radiation Oncology at Lankenau Medical Center, with Associate Principal Investigator John Devlin, MD, Bryn Mawr Hospital; site investigators Michael Dabrow, DO, at Paoli Hospital; and Rashmi Sanjay, MD, at Riddle Hospital.

“Having the NCORP available at all four acute care hospitals in the system expands the access our patients have to innovative treatment care options and highlights another way we strive to provide a superior patient experience to each Main Line Health patient,” said Diana Blade, Administrator of Cancer Clinical Trials at Lankenau Institute for Medical Research.  “Our relationship with the NCI allows us to contribute in a meaningful way to cancer research and treatments that lead to medical breakthroughs.”

Mary Kate Coghlan
Communications Specialist

Connect with MLH

New Appointments

 Well Ahead Newsletter


Copyright 2016 Main Line Health

Printed from:

The information provided in this Web site is for informational purposes only. It is not a substitute for medical advice. All medical information presented should be discussed with your healthcare professional. See additional Terms of Use at For more information, call 1.866.CALL.MLH.